Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Responsiveness to basement membrane extract as a possible trait for tumorigenicity characterization.

Murata H, Omeir R, Tu W, Lanning L, Phy K, Foseh G, Lewis AM Jr, Peden K.

Vaccine X. 2019 Jan 3;1:100004. doi: 10.1016/j.jvacx.2019.100004. eCollection 2019 Apr 11.

2.

Development of a micro-neutralization assay for ebolaviruses using a replication-competent vesicular stomatitis hybrid virus and a quantitative PCR readout.

Lee SS, Phy K, Peden K, Sheng-Fowler L.

Vaccine. 2017 Oct 4;35(41):5481-5486. doi: 10.1016/j.vaccine.2017.03.019. Epub 2017 Apr 17.

3.

RT-qPCR-based microneutralization assay for human cytomegalovirus using fibroblasts and epithelial cells.

Wang X, Peden K, Murata H.

Vaccine. 2015 Dec 16;33(51):7254-7261. doi: 10.1016/j.vaccine.2015.10.110. Epub 2015 Nov 6.

4.

A novel canine kidney cell line model for the evaluation of neoplastic development: karyotype evolution associated with spontaneous immortalization and tumorigenicity.

Omeir R, Thomas R, Teferedegne B, Williams C, Foseh G, Macauley J, Brinster L, Beren J, Peden K, Breen M, Lewis AM Jr.

Chromosome Res. 2015 Dec;23(4):663-80. doi: 10.1007/s10577-015-9474-8. Epub 2015 May 10.

5.

A mouse strain defective in both T cells and NK cells has enhanced sensitivity to tumor induction by plasmid DNA expressing both activated H-Ras and c-Myc.

Sheng-Fowler L, Tu W, Fu H, Murata H, Lanning L, Foseh G, Macauley J, Blair D, Hughes SH, Coffin JM, Lewis AM Jr, Peden K.

PLoS One. 2014 Oct 10;9(10):e108926. doi: 10.1371/journal.pone.0108926. eCollection 2014.

6.

MicroRNAs as potential biomarkers for VERO cell tumorigenicity.

Teferedegne B, Macauley J, Foseh G, Dragunsky E, Chumakov K, Murata H, Peden K, Lewis AM Jr.

Vaccine. 2014 Aug 20;32(37):4799-805. doi: 10.1016/j.vaccine.2014.05.065. Epub 2014 Jul 10.

7.

Failure-to-thrive syndrome associated with tumor formation by Madin-Darby canine kidney cells in newborn nude mice.

Brinster LR, Omeir RL, Foseh GS, Macauley JN, Snoy PJ, Beren JJ, Teferedegne B, Peden K, Lewis AM Jr.

Comp Med. 2013 Aug;63(4):323-30.

8.

A neutralization assay for respiratory syncytial virus using a quantitative PCR-based endpoint assessment.

Varada JC, Teferedegne B, Crim RL, Mdluli T, Audet S, Peden K, Beeler J, Murata H.

Virol J. 2013 Jun 15;10:195. doi: 10.1186/1743-422X-10-195.

9.

Development of a neutralization assay for influenza virus using an endpoint assessment based on quantitative reverse-transcription PCR.

Teferedegne B, Lewis AM Jr, Peden K, Murata H.

PLoS One. 2013;8(2):e56023. doi: 10.1371/journal.pone.0056023. Epub 2013 Feb 20.

10.

Mutations in the GM1 binding site of simian virus 40 VP1 alter receptor usage and cell tropism.

Magaldi TG, Buch MH, Murata H, Erickson KD, Neu U, Garcea RL, Peden K, Stehle T, DiMaio D.

J Virol. 2012 Jul;86(13):7028-42. doi: 10.1128/JVI.00371-12. Epub 2012 Apr 18.

11.

Heterogeneity of the tumorigenic phenotype expressed by Madin-Darby canine kidney cells.

Omeir RL, Teferedegne B, Foseh GS, Beren JJ, Snoy PJ, Brinster LR, Cook JL, Peden K, Lewis AM Jr.

Comp Med. 2011 Jun;61(3):243-50.

12.

Plaque purification as a method to mitigate the risk of adventitious-agent contamination in influenza vaccine virus seeds.

Murata H, Macauley J, Lewis AM Jr, Peden K.

Vaccine. 2011 Apr 12;29(17):3155-61. doi: 10.1016/j.vaccine.2011.02.041. Epub 2011 Feb 26.

PMID:
21354480
13.

Patterns of microRNA expression in non-human primate cells correlate with neoplastic development in vitro.

Teferedegne B, Murata H, Quiñones M, Peden K, Lewis AM.

PLoS One. 2010 Dec 22;5(12):e14416. doi: 10.1371/journal.pone.0014416.

14.

Tumors induced in mice by direct inoculation of plasmid DNA expressing both activated H-ras and c-myc.

Sheng-Fowler L, Cai F, Fu H, Zhu Y, Orrison B, Foseh G, Blair DG, Hughes SH, Coffin JM, Lewis AM Jr, Peden K.

Int J Biol Sci. 2010 Mar 29;6(2):151-62.

15.

A quantitative PCR assay for SV40 neutralization adaptable for high-throughput applications.

Murata H, Teferedegne B, Lewis AM Jr, Peden K.

J Virol Methods. 2009 Dec;162(1-2):236-44. doi: 10.1016/j.jviromet.2009.08.012. Epub 2009 Sep 1.

PMID:
19729038
16.

Quantitative determination of the infectivity of the proviral DNA of a retrovirus in vitro: Evaluation of methods for DNA inactivation.

Sheng-Fowler L, Lewis AM Jr, Peden K.

Biologicals. 2009 Aug;37(4):259-69. doi: 10.1016/j.biologicals.2009.04.002. Epub 2009 May 19.

PMID:
19457682
17.

Issues associated with residual cell-substrate DNA in viral vaccines.

Sheng-Fowler L, Lewis AM Jr, Peden K.

Biologicals. 2009 Jun;37(3):190-5. doi: 10.1016/j.biologicals.2009.02.015. Epub 2009 Mar 14.

PMID:
19285882
18.

Identification of a neutralization epitope in the VP1 capsid protein of SV40.

Murata H, Teferedegne B, Sheng L, Lewis AM Jr, Peden K.

Virology. 2008 Nov 10;381(1):116-22. doi: 10.1016/j.virol.2008.07.032. Epub 2008 Sep 11.

19.

Oncogenicity of DNA in vivo: tumor induction with expression plasmids for activated H-ras and c-myc.

Sheng L, Cai F, Zhu Y, Pal A, Athanasiou M, Orrison B, Blair DG, Hughes SH, Coffin JM, Lewis AM, Peden K.

Biologicals. 2008 May;36(3):184-97. doi: 10.1016/j.biologicals.2007.11.003. Epub 2008 Jan 22.

PMID:
18218323
20.
21.

Assessing the tumorigenic phenotype of VERO cells in adult and newborn nude mice.

Manohar M, Orrison B, Peden K, Lewis AM Jr.

Biologicals. 2008 Jan;36(1):65-72. Epub 2007 Oct 22.

PMID:
17933552
22.

Recovery of strains of the polyomavirus SV40 from rhesus monkey kidney cells dating from the 1950s to the early 1960s.

Peden K, Sheng L, Omeir R, Yacobucci M, Klutch M, Laassri M, Chumakov K, Pal A, Murata H, Lewis AM Jr.

Virology. 2008 Jan 5;370(1):63-76. Epub 2007 Sep 27.

23.

WHO informal consultation on the application of molecular methods to assure the quality, safety and efficacy of vaccines, Geneva, Switzerland, 7-8 April 2005.

Shin J, Wood D, Robertson J, Minor P, Peden K; WHO Informal Consultation Group.

Biologicals. 2007 Mar;35(1):63-71. Epub 2006 Feb 20.

PMID:
17321940
24.

Biological activity of residual cell-substrate DNA.

Peden K, Sheng L, Pal A, Lewis A.

Dev Biol (Basel). 2006;123:45-53; discussion 55-73.

PMID:
16566436
25.

Real-time, quantitative PCR assays for the detection of virus-specific DNA in samples with mixed populations of polyomaviruses.

Pal A, Sirota L, Maudru T, Peden K, Lewis AM Jr.

J Virol Methods. 2006 Jul;135(1):32-42. Epub 2006 Mar 9.

PMID:
16527364
26.

Complete nucleotide sequence of polyomavirus SA12.

Cantalupo P, Doering A, Sullivan CS, Pal A, Peden KW, Lewis AM, Pipas JM.

J Virol. 2005 Oct;79(20):13094-104.

27.
28.

Human immunodeficiency virus (HIV) gp41 escape mutants: cross-resistance to peptide inhibitors of HIV fusion and altered receptor activation of gp120.

Desmezieres E, Gupta N, Vassell R, He Y, Peden K, Sirota L, Yang Z, Wingfield P, Weiss CD.

J Virol. 2005 Apr;79(8):4774-81.

29.
30.

Additive activity between the trans-activation response RNA-binding protein, TRBP2, and cyclin T1 on HIV type 1 expression and viral production in murine cells.

Battisti PL, Daher A, Bannwarth S, Voortman J, Peden KW, Hiscott J, Mouland AJ, Benarous R, Gatignol A.

AIDS Res Hum Retroviruses. 2003 Sep;19(9):767-78.

PMID:
14585207
31.
32.

Replication of HIV-1 deleted Nef mutants in chronically immune activated human T cells.

Shapira-Nahor O, Maayan S, Peden KW, Rabinowitz R, Schlesinger M, Alian A, Panet A.

Virology. 2002 Nov 10;303(1):138-45.

33.

Increased replication of non-syncytium-inducing HIV type 1 isolates in monocyte-derived macrophages is linked to advanced disease in infected children.

Tuttle DL, Anders CB, Aquino-De Jesus MJ, Poole PP, Lamers SL, Briggs DR, Pomeroy SM, Alexander L, Peden KW, Andiman WA, Sleasman JW, Goodenow MM.

AIDS Res Hum Retroviruses. 2002 Mar 20;18(5):353-62.

PMID:
11897037
34.

A defined-risks approach to the regulatory assessment of the use of neoplastic cells as substrates for viral vaccine manufacture.

Lewis AM Jr, Krause P, Peden K.

Dev Biol (Basel). 2001;106:513-35. No abstract available.

PMID:
11761266
35.

Application of quantitative methods for the detection of adventitious agents.

Peden K, Lewis AM Jr, Maudru T.

Dev Biol (Basel). 2001;106:333-9. No abstract available.

PMID:
11761246
36.

Detection and characterization of porcine endogenous retrovirus in porcine plasma and porcine factor VIII.

Takefman DM, Wong S, Maudru T, Peden K, Wilson CA.

J Virol. 2001 May;75(10):4551-7.

37.

Use of a quantitative product-enhanced reverse transcriptase assay to monitor retrovirus levels in mAb cell-culture and downstream processing.

Brorson K, Swann PG, Lizzio E, Maudru T, Peden K, Stein KE.

Biotechnol Prog. 2001 Jan-Feb;17(1):188-96. Erratum in: Biotechnol Prog 2001 May-Jun;17(3):586.

PMID:
11170498
38.

Coreceptors for human immunodeficiency virus and simian immunodeficiency virus.

Peden KW, Farber JM.

Adv Pharmacol. 2000;48:409-78. Review. No abstract available.

PMID:
10987098
39.

Mass spectrometric detection for capillary isoelectric focusing separations of complex protein mixtures.

Jensen PK, Pasa-Tolić L, Peden KK, Martinović S, Lipton MS, Anderson GA, Tolić N, Wong KK, Smith RD.

Electrophoresis. 2000 Apr;21(7):1372-80.

PMID:
10826683
40.

CCR9A and CCR9B: two receptors for the chemokine CCL25/TECK/Ck beta-15 that differ in their sensitivities to ligand.

Yu CR, Peden KW, Zaitseva MB, Golding H, Farber JM.

J Immunol. 2000 Feb 1;164(3):1293-305.

41.

Different functions are required for initiation and maintenance of immortalization of rat embryo fibroblasts by SV40 large T antigen.

Powell AJ, Darmon AJ, Gonos ES, Lam EW, Peden KW, Jat PS.

Oncogene. 1999 Dec 2;18(51):7343-50.

42.
43.

Adaptation of the fluorogenic 5'-nuclease chemistry to a PCR-based reverse transcriptase assay.

Maudru T, Peden KW.

Biotechniques. 1998 Dec;25(6):972-5. No abstract available.

44.

Human immunodeficiency virus type 1 infection of antigen-specific CD4 cytotoxic T lymphocytes.

Robbins PA, Roderiquez GL, Peden KW, Norcross MA.

AIDS Res Hum Retroviruses. 1998 Nov 1;14(16):1397-406.

PMID:
9824317
46.

The reverse transcriptase activity in cell-free medium of chicken embryo fibroblast cultures is not associated with a replication-competent retrovirus.

Khan AS, Maudru T, Thompson A, Muller J, Sears JF, Peden KW.

J Clin Virol. 1998 Jul 24;11(1):7-18.

PMID:
9784139
47.

CXCR4 and CCR5 on human thymocytes: biological function and role in HIV-1 infection.

Zaitseva MB, Lee S, Rabin RL, Tiffany HL, Farber JM, Peden KW, Murphy PM, Golding H.

J Immunol. 1998 Sep 15;161(6):3103-13.

48.

Effects of mutations within the SV40 large T antigen ATPase/p53 binding domain on viral replication and transformation.

Peden KW, Srinivasan A, Vartikar JV, Pipas JM.

Virus Genes. 1998;16(2):153-65.

PMID:
9608660
50.

Extrachromosomal unequal homologous recombination and gene conversion in simian kidney cells: effects of UV damage.

Gening L, Takeshita M, Levine RL, Peden KW, Grollman AP.

Mutat Res. 1998 Feb;407(1):11-24.

PMID:
9539977

Supplemental Content

Support Center